SCHEMBL4305804

SCHEMBL4305804

O=C(Cc1ccc(C(F)(F)F)cc1)Cc1ccc(C(F)(F)F)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.56
HDAC1 Q13547 1/20 0.56
HDAC8 Q9BY41 1/20 0.56
CES2 O00748 1/20 0.52
CES1 P23141 1/20 0.52
SRD5A2 P31213 1/20 0.50
RXRA P19793 1/20 0.50
RXRB P28702 1/20 0.50
RXRG P48443 1/20 0.50
PSEN1 P49768 1/20 0.50
PSEN2 P49810 1/20 0.50
APH1B Q8WW43 1/20 0.50
NCSTN Q92542 1/20 0.50
APH1A Q96BI3 1/20 0.50
PSENEN Q9NZ42 1/20 0.50
CNR2 P34972 2/20 0.49
NLRP3 Q96P20 1/20 0.49
PTPN1 P18031 1/20 0.48
GSK3B P49841 1/20 0.48
TAAR1 Q96RJ0 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5161111 0.92 CNR2 (0.58) PIK3CAHDAC1HDAC8CES2CES1
SCHEMBL17634087 0.88 GSK3B (0.56) PIK3CAHDAC1HDAC8CES2CES1
SCHEMBL4657783 0.88 PIK3CA (0.50) PIK3CAHDAC1HDAC8CES2CES1
SCHEMBL26384373 0.88 TAAR1 (0.52) PIK3CAHDAC1HDAC8CES2CES1
SCHEMBL30628135 0.85 PIK3CA (0.47) PIK3CAHDAC1HDAC8CES2CES1
SCHEMBL267205 0.84 RXRA (0.68) PIK3CAHDAC1HDAC8CES2CES1
SCHEMBL15515090 0.84 PIK3CA (0.54) PIK3CAHDAC1HDAC8CES2CES1
SCHEMBL2269018 0.83 RXRA (0.53) PIK3CAHDAC1HDAC8RXRARXRB
SCHEMBL265118 0.83 PIK3CA (0.53) PIK3CAHDAC1HDAC8CES2CES1
Hydrochloric Acid SCHEMBL2528774 0.83 RXRA (0.66) PIK3CAHDAC1HDAC8SRD5A2RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065371-A1 Chiral organic catalysts for the stereoselective reduction of carbon-nitrogen double bonds for the preparation of enantiomerically enriched amines UNIVERSITA'DEGLI STUDI DI MILANO (IT) 2009-06-03 EP disclosed
US-6797842-B2 BY ASYMMETRICALLY REDUCING AN OPTICALLY ACTIVE IMINE, USING A HYDRIDE REDUCING AGENT TO CONVERT TO AN OPTICALLY ACTIVE SECONDARY AMINE, WHICH THEN UNDERGOES HYDROGENOLYSIS; HIGH OPTICAL PURITY, SIMPLE, EFFICIENT CENTRAL GLASS COMPANY, LIMITED (JP) 2004-09-28 US disclosed
US-20020103400-A1 Process for producing optically active 1-(fluoro- or trifluoromethyl-substituted phenyl) ethylamine and process for purifying same CENTRAL GLASS COMPANY, LIMITED (JP) 2002-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103400-A1 Process for producing optically active 1-(fluoro- or trifluoromethyl-substituted phenyl) ethylamine and process for purifying same MAP2K5, MAP2K4, MAP2K1 PIK3CA 2492/4885HDAC1 883/4885HDAC8 1039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.